Coumarin-derived azolyl ethanols: synthesis, antimicrobial evaluation and preliminary action mechanism

Peng, Xin-Mei; Kumar, Kannekanti Vijaya; Damu, Guri L.V.; Zhou, Cheng‐He

doi:10.1007/s11426-015-0351-0

Cited by 60 publications

(24 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further study indicated that coumarin–1,2,4‐triazole hybrid 8a (MIC: 4–32 µg/ml) and its bis‐1,2,4‐triazole analog 8b (MIC: 1–32 µg/ml) showed improved activity against MRSA, B. subtilis , M. luteus , E. coli , P. aeruginosa , and S. dysenteriae . [ 46 ] In particular, compound 8b was comparable to chloramphenicol (MIC: 8–32 µg/ml) and norfloxacin (MIC: 1–16 µg/ml) against the tested pathogens. The mechanism study revealed that hybrid 8b could interact with calf thymus DNA to form 8b –DNA complex via both hydrogen bonds and the van der Waals force, which might be the factor to exert the powerful antibacterial activity.…”

Section: Coumarin–triazole Hybridsmentioning

confidence: 99%

Coumarin‐containing hybrids and their antibacterial activities

Feng

Zhang

Yang

et al. 2020

Archiv der Pharmazie

View full text Add to dashboard Cite

Infections caused by Gram-positive and -negative bacteria are one of the foremost causes of morbidity and mortality globally. Antibiotics are the mainstay of therapy for bacterial infections, but the emergence and wide spread of drug-resistant pathogens have already become a huge issue for public healthcare systems. The coumarin moiety, which is ubiquitous in nature, could bind to the B subunit of DNA gyrase in bacteria and inhibit DNA supercoiling by blocking the ATPase activity; hence, coumarin derivatives possess potential antibacterial activity. Several coumarin-containing hybrids such as coumermycin A1, clorobiocin, and novobiocin have already been used in clinical practice for the treatment of various bacterial infections; thus, it is conceivable that hybridization of the coumarin moiety with other antibacterial pharmacophores may provide opportunities for the development of novel antibiotics. This review outlines the advances in coumarin-containing hybrids with antibacterial potential in the recent 5 years and the structure-activity relationships are also discussed. K E Y W O R D S antibacterial, coumarin, hybrid compounds, structure-activity relationships

show abstract

Section: Coumarin–triazole Hybridsmentioning

confidence: 99%

Coumarin‐containing hybrids and their antibacterial activities

Feng

Zhang

Yang

et al. 2020

Archiv der Pharmazie

View full text Add to dashboard Cite

show abstract

“…85 The paper disc method was utilized for the anti-bacterial screening of these analogues against Escherichia coli (MTCC 443) and Azolyl ethanol fragment is widely present in various biologically-active compounds. 86 Many azolyl ethanols have been successfully developed and are used to treat clinical infections (uconazole and voriconazole, which are triazole type of azolyl ethanol, are used as rst line drugs to treat fungal infections). 87 Various azolyl ethanol fragments such as imidazolyl, triazolyl, tetrazolyl, benzoimidazolyl, and benzotriazolyl were incorporated at the 3 rd position of quinazolin-4(3H)one by Peng et al to get a series of hybrid analogues as potent antimicrobial agents.…”

Section: Anti-microbial Hybridsmentioning

confidence: 99%

Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids

2020

View full text Add to dashboard Cite

show abstract

“…In 2016, Zhou and coworkers [92] synthesised and characterised 7-[2-hydroxy-3-(1H-imidazol-1-yl)propoxy]-4-methyl-2H-chromen-2-ones 154a-e via the route shown in Scheme 28, in which compound 155, which was prepared in two steps form resorcinol (156), was the key intermediate. Treatment of 155 with the appropriate imidazoles 157 in EtOH using K 2 CO 3 as base afforded hybrids 154 in yields ranging from 24 to 61%.…”

Section: Coumarin/imidazole Hybrids and Conjugatesmentioning

confidence: 99%

An Updated Review on the Synthesis and Antibacterial Activity of Molecular Hybrids and Conjugates Bearing Imidazole Moiety

Rossi

Ciofalo

2020

Molecules

View full text Add to dashboard Cite

The rapid growth of serious infections caused by antibiotic resistant bacteria, especially the nosocomial ESKAPE pathogens, has been acknowledged by Governments and scientists and is one of the world’s major health problems. Various strategies have been and are currently investigated and developed to reduce and/or delay the bacterial resistance. One of these strategies regards the design and development of antimicrobial hybrids and conjugates. This unprecedented critical review, in which our continuing interest in the synthesis and evaluation of the bioactivity of imidazole derivatives is testified, aims to summarise and comment on the results obtained from the end of the 1900s until February 2020 in studies conducted by numerous international research groups on the synthesis and evaluation of the antibacterial properties of imidazole-based molecular hybrids and conjugates in which the pharmacophoric constituents of these compounds are directly covalently linked or connected through a linker or spacer. In this review, significant attention was paid to summarise the strategies used to overcome the antibiotic resistance of pathogens whose infections are difficult to treat with conventional antibiotics. However, it does not include literature data on the synthesis and evaluation of the bioactivity of hybrids and conjugates in which an imidazole moiety is fused with a carbo- or heterocyclic subunit.

show abstract

Coumarin-derived azolyl ethanols: synthesis, antimicrobial evaluation and preliminary action mechanism

Cited by 60 publications

References 53 publications

Coumarin‐containing hybrids and their antibacterial activities

Coumarin‐containing hybrids and their antibacterial activities

Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids

An Updated Review on the Synthesis and Antibacterial Activity of Molecular Hybrids and Conjugates Bearing Imidazole Moiety

Contact Info

Product

Resources

About